Pinnacle Life Science Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Pinnacle Life Science Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pinnacle Life Science Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.5M Trade | TransData Nexus

Pinnacle Life Science Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $1.5M Total Trade · DGFT Verified

Pinnacle Life Science Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.5M across 2 products in 2 therapeutic categories. Based on 40 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bisoprolol ($1.1M), Norfloxacin ($400.0K), .

Pinnacle Life Science Private Limited — Export Portfolio & Destination Treemap

Pinnacle Life Science Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Pinnacle Life Science Private Limited? — Company Overview & Market Position

Pinnacle Life Science Private Limited, established on January 15, 2003, is a private limited company headquartered in Baddi, Himachal Pradesh, India. It operates under the Corporate Identification Number (CIN) U24232HP2003PTC030912. The company is a subsidiary of Aarti Drugs Limited, a prominent player in the pharmaceutical industry, and is part of the $1.5 billion Aarti Group conglomerate.

As of the latest available data, Pinnacle Life Science has an authorized share capital of ₹100 million and a paid-up capital of ₹77.8275 million. The company has experienced growth in recent years, with a 9.78% increase in total revenue for the financial year ending March 31, 2024. Profitability has also improved, with a 109.39% increase in profit during the same period.

What Does Pinnacle Life Science Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Bisoprolol$1.1M 2Norfloxacin

Product Portfolio — Top 2 by Export Value

Pinnacle Life Science Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bisoprolol	Cardiovascular	$1.1M	32	1.3%	12
2	Norfloxacin	Advanced Antibiotics	$400.0K	8	4.8%	2

Pinnacle Life Science Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.5M. The top category is Cardiovascular (73.0% of portfolio), followed by Advanced Antibiotics (27.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Pinnacle Life Science Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Pinnacle Life Science operates a state-of-the-art manufacturing facility in Baddi, Himachal Pradesh. This plant has received approvals from the US FDA and multiple Good Manufacturing Practice (GMP) certifications, including those from the Medicines Control Authority of Zimbabwe (MCAZ) and the General Directorate of Medicines and Medical Devices of Peru (DIGEMID).

3Key Leadership

The company's leadership includes Managing Director Vishwa Harshit Savla, appointed on September 8, 2014, and Director Neha Rajen Gada, appointed on July 1, 2024. Other key executives include Harshit Manilal Savla, Harit Pragji Shah, Adhish Prakash Patil, and Parth Samir Shah.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Pinnacle Life Science Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Pinnacle Life Science has made significant strides in regulated markets. In April 2023, the company successfully completed a US FDA audit for its oncology block, marking a significant achievement in its global expansion efforts. Additionally, in June 2023, the company passed a UK Medicines and Healthcare products Regulatory Agency (MHRA) audit, further solidifying its presence in the European market.

2Emerging Markets

The company has expanded its reach to over 90 countries, including emerging markets in Africa, Latin America, and Southeast Asia. Its manufacturing facility has received GMP approvals from regulatory bodies such as MCAZ Zimbabwe and DIGEMID Latin America, facilitating access to these regions.

3Geographic Strategy

Pinnacle Life Science's export portfolio is concentrated, with its top five products accounting for 100% of its export value. This indicates a high level of concentration risk. The company's strategic direction appears to focus on consolidating its position in key markets, leveraging its manufacturing capabilities and regulatory approvals to expand its global footprint.

Pinnacle Life Science Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Pinnacle Life Science's manufacturing facility in Baddi, Himachal Pradesh, has been registered with the US FDA. In April 2023, the company successfully completed a US FDA audit for its oncology block, marking a significant achievement in its global expansion efforts.

2WHO & EU GMP

The company has received GMP approvals from the Medicines Control Authority of Zimbabwe (MCAZ) and the General Directorate of Medicines and Medical Devices of Peru (DIGEMID), facilitating access to these regions.

3CDSCO & Indian Regulatory

Pinnacle Life Science holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India. The company's registered address is Near Telephone Exchange, Manpura, Baddi, Himachal Pradesh 173205, India.

4Recent Regulatory Actions

Pinnacle Life Science Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Pinnacle Life Science operates in a competitive landscape with several key players in the pharmaceutical export market. While specific market share data is not available, the company's focus on high-quality manufacturing and regulatory compliance positions it favorably against competitors.

2Key Differentiators

Pinnacle Life Science's key differentiators include its state-of-the-art manufacturing facility in Baddi, Himachal Pradesh, which has received approvals from the US FDA and multiple GMP certifications. The company's diverse product portfolio spans oncology, cardiovascular, anti-infectives, and diabetes segments, catering to a wide range of therapeutic areas.

3Strategic Position

Pinnacle Life Science's current strategic direction focuses on expanding its presence in both regulated and emerging markets. The company's recent regulatory approvals and successful audits indicate a strong commitment to quality and compliance. Future outlook appears positive, with plans to launch new products in oncology, cardiovascular, and anti-infective segments.

Buyer Due Diligence Brief — Evaluating Pinnacle Life Science Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Pinnacle Life Science has demonstrated a strong track record in manufacturing and exporting pharmaceutical products. The company's export value of $1.5 million USD across 40 shipments indicates a consistent export volume. The high concentration of its export portfolio suggests a focused approach, which may be advantageous for partners seeking specialized products.

2Certifications to Verify

Importers should verify the following certifications when considering Pinnacle Life Science as a supplier:

FDA Registration: Confirm the company's registration status with the US FDA.

WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practice certification.

Frequently Asked Questions — Pinnacle Life Science Private Limited

How many pharmaceutical products does Pinnacle Life Science Private Limited export from India?

Pinnacle Life Science Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Bisoprolol ($1.1M), Norfloxacin ($400.0K). Total export value is $1.5M.

What is Pinnacle Life Science Private Limited's total pharmaceutical export value?

Pinnacle Life Science Private Limited's total pharmaceutical export value is $1.5M, based on 40 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Pinnacle Life Science Private Limited cover?

Pinnacle Life Science Private Limited exports across 2 therapeutic categories. The largest are Cardiovascular (73.0%, 1 products), Advanced Antibiotics (27.0%, 1 products).

Get Full Pinnacle Life Science Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.